Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil
| dc.creator | Tália Santana Machado de Assis | |
| dc.creator | Mariana Lourenço Freire | |
| dc.creator | Janaína de Pina Carvalho | |
| dc.creator | Ana Rabello | |
| dc.creator | Glaucia Fernandes Cota | |
| dc.date.accessioned | 2023-12-07T22:52:07Z | |
| dc.date.accessioned | 2025-09-08T23:15:31Z | |
| dc.date.available | 2023-12-07T22:52:07Z | |
| dc.date.issued | 2022-02-25 | |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.1371/journal.pone.0264159 | |
| dc.identifier.issn | 1932-6203 | |
| dc.identifier.uri | https://hdl.handle.net/1843/61860 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Plos One | |
| dc.rights | Acesso Aberto | |
| dc.subject | Teste para COVID-19 | |
| dc.subject | Avaliação de Custo-Efetividade | |
| dc.subject | Brasil | |
| dc.subject.other | Anti-SARS-CoV-2 | |
| dc.subject.other | Diagnostic tests | |
| dc.subject.other | Cost-effectiveness | |
| dc.subject.other | Brazil | |
| dc.title | Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 13 | |
| local.citation.issue | 2 | |
| local.citation.spage | 1 | |
| local.citation.volume | 17 | |
| local.description.resumo | Background Although serologic tests for COVID-19 diagnosis are rarely indicated nowadays, they remain commercially available and widely used in Brazil. The objective of this study was to evaluate the cost-effectiveness of anti-SARS-CoV-2antibody diagnostic tests for COVID-19 in Brazil. Methods Eleven commercially available diagnostic tests, comprising five lateral-flow immunochromatographic assays (LFAs) and six immunoenzymatic assays (ELISA) were analyzed from the perspective of the Brazilian Unified Health System. Results The direct costs of LFAs ranged from US$ 11.42 to US$ 17.41and of ELISAs, from US$ 6.59 to US$ 10.31. Considering an estimated disease prevalence between 5% and 10%, the anti-SARS-CoV-2 ELISA (IgG) was the most cost-effective test, followed by the rapid One Step COVID-19 Test, at an incremental cost-effectiveness ratio of US$ 2.52 and US$ 1.26 per properly diagnosed case, respectively. Considering only the LFAs, at the same prevalence estimates, two tests, the COVID-19 IgG/IgM and the One Step COVID-19 Test, showed high effectiveness at similar costs. For situations where the estimated probability of disease is 50%, the LFAs are more costly and less effective alternatives. Conclusions Nowadays there are few indications for the use of serologic tests in the diagnosis of COVID-19 and numerous commercially available tests, with marked differences are observed among them. In general, LFA tests are more cost-effective for estimated low-COVID-19- prevalences, while ELISAs are more cost-effective for high-pretest-probability scenarios. | |
| local.identifier.orcid | https://orcid.org/0000-0003-0538-7403 | |
| local.publisher.country | Brasil | |
| local.publisher.department | HCL - HOSPITAL DAS CLINICAS | |
| local.publisher.department | MEDICINA - FACULDADE DE MEDICINA | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0264159 |